Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 21c
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Join SI Premium – FREE
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.43), $0.21 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $173.91 million versus the consensus estimate of $167.33 million.
For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- JetStream Announces Clearance, an AI Zero Trust Reasoning Engine
- Quanome Technologies (QNME) files $250M mixed shelf
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
